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Performance of a new quantitative 
computed tomography index for 
interstitial lung disease assessment 
in systemic sclerosis
Marialuisa Bocchino1, Dario Bruzzese2, Michele D’Alto3, Paola Argiento3, Alessia Borgia  4,  
Annalisa Capaccio1, Emanuele Romeo3, Barbara Russo4, Alessandro Sanduzzi1, 
Tullio Valente5, Nicola Sverzellati6, Gaetano Rea5 & Serena Vettori  4
Quantitative high resolution computed tomography (HRCT) may objectively assess systemic sclerosis 
(SSc)-interstitial lung disease (ILD) extent, using three basic densitometric measures: mean lung 
attenuation (MLA), skewness, and kurtosis. This prospective study aimed to develop a composite 
index - computerized integrated index (CII) – that accounted for MLA, skewness, and kurtosis by 
means of Principal Component Analysis over HRCTs of 83 consecutive SSc subjects, thus eliminating 
redundancies. Correlations among CII, cardiopulmonary function and immune-inflammatory 
biomarkers (e.g. sIL-2Rα and CCL18 serum levels) were explored. ILD was detected in 47% of patients 
at visual HRCT assessment. These patients had worse CII values than patients without ILD. The CII 
correlated with lung function at both baseline and follow-up, and with sIL-2Rα and CCL18 serum levels. 
The best discriminating CII value for ILD was 0.1966 (AUC = 0.77; sensitivity = 0.81 [95%CI:0.68–0.92]; 
specificity = 0.66 [95%CI:0.52–0.80]). Thirty-four percent of patients without visual trace of ILD had 
a CII lower than 0.1966, and 67% of them had a diffusing lung capacity for CO <80% of predicted. We 
showed that this new composite CT index for SSc-ILD assessment correlates with both lung function 
and immune-inflammatory parameters and could be sufficiently sensitive for capturing early lung 
density changes in visually ILD-free patients.
Interstitial lung disease (ILD) is a leading cause of disability and mortality in systemic sclerosis (SSc)1,2, a chronic 
multiorgan disease characterized by autoimmune phenomena, microangiopathy, and fibrosis of the skin and 
internal organs3–5.
High resolution computed tomography (HRCT) detects SSc-ILD in up to 90% of cases6–8. In 2008, Goh et al. 
proposed a visual scoring of the total extent of SSc-ILD at HRCT that improved the prediction of mortality at 
follow-up (FU)9. These results were also confirmed by subsequent studies10,11.
However, this visual scoring of the extent of SSc-ILD remains affected by significant intra- and inter-observer 
variability12,13. Basic density-based CT analysis, such as mean lung attenuation (MLA, average global attenuation 
value of lung parenchyma), skewness (degree of histogram asymmetry) and kurtosis (degree of histogram peak-
edness), is widely available and could replace the visual scoring for SSc-ILD assessment14–16. This method also 
showed higher sensitivity as compared to the visual scoring15. Furthermore, densitometric parameters correlate 
with several functional indexes, such as forced vital capacity (FVC), diffusing lung capacity for carbon oxide 
(DLCO), and oxygen desaturation during the 6-minute walking test (6-MWT), and quality of life15,17,18.
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In order to develop a single composite densitometric index for SSc-ILD quantification integrating MLA, skew-
ness and kurtosis, we investigated a prospective series of SSc patients by low-dose thin section volumetric lung 
CT and searched for associations of this index with cardiopulmonary function parameters, and circulating mark-
ers of immune system activation (e.g. soluble interleukin-2 receptor alpha - sIL-2Rα - and chemokine CCL18) 
previously implicated in SSc and in SSc-ILD progression19–22.
Materials and Methods
Patients. SSc patients meeting the American College of Rheumatology/European League Against 
Rheumatism classification criteria23 consecutively visited at our outpatient clinic from July 2014 to July 2015 and 
giving written informed consent to the study were enrolled. Demographics, clinical and laboratory data instru-
mental to subset classification, that is either limited (lc) or diffuse (dc) cutaneous SSc24, and to organ/system 
involvement assessment according to international requirements25 [Supplementary Table S1], were collected. SSc 
specific autoantibodies were searched as previously described26. Disease duration was evaluated from Raynaud’s 
phenomenon (RP) onset. Spirometry, lung volume measurements and determination of the haemoglobin (Hb)-
adjusted single-breath DLCO were performed at baseline and one year later using a computer-assisted spirometer 
(Quark PFT, Cosmed), according to international standards27–29. The 6-MWT was performed by trained hospital 
staff according to guidelines30. Standard echocardiography and Tissue Doppler Imaging were performed with a 
commercially available equipment (Philips iE33 ultrasound machine, Philips Medical Systems, Andover, MA) 
and a 2.5- or 3.5-MHz transducer by two highly trained cardiologists (MD and PA)31, according to international 
recommendations32. Patients with pulmonary hypertension (PH) and chronic obstructive pulmonary disease 
(COPD) were excluded from the analysis.
Serum levels of sIL-2Rα and CCL18 were measured by suspension immunoassays (Merk Millipore, Billerica, 
MA, USA) and read by a double laser-based fluorimetric instrument (Luminex 200, Luminex Corporation, 
Austin, TX, USA), according to manufacturer instructions.
We conducted our study in compliance with the principles of the revised Declaration of Helsinki and the study 
protocol was approved by the “Seconda Università degli studi di Napoli- Azienda Ospedaliera Universitaria SUN- 
AORN OSPEDALE DEI COLLI” Ethics committee (protocol n. 407/July 17th 2014).
Low-dose volumetric HRCT. Low-dose volumetric HRCT examinations were obtained with both a 
16 slice multi-detector CT scanner (MDCT 16 Brilliance Philips, Eindhoven, the Netherlands) and a 64 slice 
multi-detector CT scanner (MDCT 64, General Electric Medical System, Milwaukee, WI), with patients in supine 
position, at full inspiration33–35. Scanning parameters were 120 kV and 80 mAs, by applying the smallest field of 
view according with the to patient body habitus. Matrix size was 512 × 512 pixels; images were reconstructed 
with a 1/1.25 mm slice thickness using bone filters. The whole chest volume was processed and stored on a picture 
archiving and communication system for post-processing evaluation (Dicom images). Lung parenchyma was 
independently analysed by two ILD-expert radiologists (GR and TV) with a window width of 1.600 Hounsfield 
Units (HU) and level −600 HU. The total ILD extent was visually assessed using the scoring system proposed 
by Goh et al.9. MLA, skewness, and kurtosis were calculated using a free open-source software for digital image 
processing (Image J, 1.51 I version, developed by the National Institutes of Health of the United States). Sampling 
of the whole lung volume was performed on axial HRCT images, after that anatomical structures that could lead 
to errors in the assessment of lung parenchyma density, such as trachea, bronchi and additional areas of the chest 
wall, were manually excluded as previously reported14,36. By digital image processing MLA, skewness, and kur-
tosis were then computed slice by slice and automatically generated averaged values from all slices were used for 
the development of a single index.
Computerized integrated index development. MLA, skewness and kurtosis were combined in a single 
computerized integrated index (CII) using Principal Component Analysis (PCA)37. PCA is a data reduction tech-
nique where p variables measured on n subjects are combined to determine a new set of variables, called Principal 
Components, each of which represents a linear combination of the original variables and allows to explain a max-
imum but decreasing quota of the variability enclosed in the original dataset. In case of highly correlated variables 
(as MLA, skewness and kurtosis are), the first Principal Component accounts for the maximal amount of total 
variance in the observed variables and can be used to parsimoniously express the latent information shared by all 
of them thus discarding any redundancy. Each component is expressed by a set of p weights, one for each of the 
original variables, that is used to compute the subjects’ score on these new variables according to the following 
expression:
= + + … +C b x b x , b xij j 1 1i j 2 2i i pi
where jCi is the score on the j-th component (j = 1, ..., n) for the i-th subject (i = 1, …, n), x1i,… xpi are the values 
of the i-th subject on the p original variables and jbi,… jbp represent the weights associated to the j-th component. 
The CII is, therefore, an a-dimensional index as in the PCA the components were standardized in order to give all 
of them equal weight in the data analysis.
The CII explained the 93.8% of the total variability. With respect to the original variables, this component 
showed a negative correlation with MLA (r = −0.94) and was positively correlated with skewness (r = +0.99) and 
kurtosis (r = +0.97). This correlation pattern allowed the assignment of a meaningful interpretation to the index, 
e.g. the lower the value of the CII is, the more severe the lung involvement is.
Statistical analysis. The statistical platform R (The R Foundation for Statistical Computing) was used for 
all statistical analyses. Numerical variables were synthesized using mean ± standard deviation (SD) or, in case 
of consistent asymmetry in their distribution, using median with either range or inter-quartile range (IQR). 
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Categorical variables were summarized using absolute frequencies and percentages. Differences between groups 
were accordingly assessed using either the t test for independent samples or the Mann Whitney U test in case 
of numerical variables and the chi-square test, or the Fisher exact test when appropriate, in case of categorical 
factors.
General linear models or logistic regression were used to adjust the analysis for confounding factors. 
Correlation and partial correlation were based on Pearson correlation coefficient.
Concordance between radiologists was measured using the Concordance Correlation Coefficient38 for quan-
titative measurements or by the Cohens’ Kappa index for dichotomic assessment. Diagnostic accuracy of the 
CII was measured using the area under the curve (AUC) of the corresponding receiver operating characteris-
tic curve. The threshold for optimal classification accuracy was selected according to the maximization of the 
Youden Index.
Results
SSc patient characteristics. A total of 83 patients (79 females; mean age 56.4 ± 11.3 years) were enrolled 
in the current study. Seventeen (20.5%) had dcSSc and 66 (79.5%) lcSSc, with a median disease duration of 12 
years (range 2–54). At visual assessment, ILD was detected in 39 (47%) patients, with a non-specific interstitial 
pneumonia (NSIP) pattern in 36 (43.4%) and a usual interstitial pneumonia pattern (UIP) in 3 (3.6%). Twenty out 
of the 39 (51.3%) SSc-ILD patients had an extensive disease according to the Goh score (e. g. >20%) with a 100% 
agreement between the two radiologists. Differences between patients with and without ILD in demographic, 
serological and clinical features are summarized in Table 1, with the exception of lung function that is detailed in 
Table 2. As expected, patients with ILD were mostly dcSSc, anti-topoisomerase-I antibody (ATA) positive with 
a shorter disease duration, and were more frequently treated with low-dose glucocorticoids and/or immuno-
suppressants (Table 1). Moreover, they had higher sIL-2Rα and CCL18 levels (Table 1), impaired lung function, 
and higher oxygen desaturation under effort (Table 2). There were no differences in terms of cardiac function 
between subjects with ILD and those without ILD (Supplementary Table S2), with the exception of an estimated 
systolic pulmonary artery pressure that was slightly higher in patients with ILD (30 mmHg [IQR 28.5–35] versus 
28 [25–31.5]; p = 0.02).
CII correlations at baseline. Density histogram analysis and CII evaluation are summarized in Fig. 1 (pan-
els A-D). The CII discriminated between ILD and non-ILD SSc patients (p < 0.001), as patients with ILD has sig-
nificantly lower CII values as compared to non-ILD patients (Fig. 1D). The best CII discriminating cut-off value 
Figure 1. (A–D) Distribution of densitometric parameter values derived from the analysis of low-dose thin 
section volumetric lung CT in SSc patients without ILD in comparison with SSc-ILD cases. MLA, skewness 
and kurtosis are shown in panel (A–C), respectively. Distribution of CII values is shown in panel (D). The lower 
the value is for MLA and CII, the more severe the lung involvement is; on the contrary the higher the value is 
for skewness and kurtosis, the more severe the lung involvement is. (E) Diagnostic accuracy of CII by means 
of receiver-operating characteristic curve analysis. (F) CII in patients with limited (<20%) ILD in comparison 
with extended ILD (>20%), as assessed by the Goh visual score10. Lines represent mean ± standard deviation. 
CT = computed tomography; SSc = systemic sclerosis; ILD = interstitial lung disease; MLA = mean lung 
attenuation; CII = computerized integrated index; AUC = area under the curve; CI = confidence interval.
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for ILD cases was <0.1966 with a sensitivity and a specificity of 0.81 and 0.66, respectively, and an AUC of 0.77. 
The CII was also strongly associated with the Goh score (Fig. 1F).
In keeping with the visual assessment (Table 1), the CII correlated with the body mass index (BMI) (r = −0.42; 
p < 0.001) and the disease duration (r = 0.22; p = 0.044); it was significantly lower in dcSSc as compared with 
lcSSc patients (−0.5144 ± 1.174 vs. 0.2277 ± 0.872; p = 0.019), in ATA positive subjects as compared with the 
other autoantibodies (−0.4049 ± 1.114 vs. 0.3249 ± 0.817; p = 0.008), and in subjects under previous or current 
treatment with cyclophosphamide (−0.2117 ± 0.972 versus 0.4165 ± 0.823; p = 0.003). Furthermore, the CII neg-
atively correlated with sIL-2Rα and CCL18 serum levels (r = −0.27, p = 0.03; r = −0.34, p = 0.005, respectively), 
and with lung function and exercise performance parameters (Table 3). All of these differences remained signif-
icant after adjusting for BMI and disease duration. The CII accuracy in identifying patients with an FVC < 80% 
of predicted was of 0.77, the optimal cut-off being < −0.73 (57% sensitivity and 94% specificity) (Fig. 2A). The 
CII threshold of +0.68 differentiated patients with a DLCO < 80% of predicted with a sensitivity of 77% and a 
specificity of 64% (Fig. 2B). In 15/44 patients (34%) with no evidence of ILD at visual examination, the CII was 
Characteristics
All patients 
(n = 83;%)
ILD+ ILD−
p*(n = 39;%) (n = 44; %)
Demographics
Female 79 (95) 37 (94.87) 42 (95.45) 1
Age in years (mean±SD) 56.4 ± 11.3 56.51 ± 11.77 56.58 ± 10.61 0.979
BMI (median, range) 26 (19–40) 28 (19–40) 25 (20–39) 0.06
History of or current smoking attitude 41 (49.4) 14 (35.89) 27 (61.36) 0.028
Disease subtype and clinical manifestations
lcSSc 66 (79.5) 25 (64.1) 41 (93.2)
dcSSc 17 (20.5) 14 (35.9) 3 (6.8) 0.002
Years from 1st non-RP symptom (median, range) 12 (2–54) 9 (2–49) 14 (2–54) 0.018
ANA 83 (100) 39 (100) 44 (100) —
ACA 33 (39.76) 3 (7.69) 30 (68.18) <0.001
ATA 35 (42.2) 32 (82.05) 3 (6.82) <0.001
Anti-RNA pol III Ab 2 (2.4) 2 (5.13) 0 —
Anti-Pm-Scl Ab 0 0 0 —
Anti-fibrillarin Ab 0 0 0 —
Anti-Th/To Ab 0 0 0 —
Negative SSc-marker Ab 13 (15.66) 2 (5.13) 11 (25) 0.016
RP 83 (100) 39 (100) 44 (100) —
History of and/or active DU and/or pitting scars 32 (38.55) 19 (48.72) 13 (29.55) 0.11
mRSS (median, range) 2 (0–28) 3 (0–26) 1 (0–8) 0.001
Joint/tendon involvement 37 (44.58) 19 (48.72) 18 (40.91) 0.513
Muscle involvement 3 (3.61) 1 (2.56) 2 (4.55) 1
Gastrointestinal involvement 59 (71.08) 27 (69.23) 32 (72.72) 0.81
Kidney involvement 0 0 0 —
Circulating markers of immune system activation
sIL2-Rα (pg/ml; median, range)
125.4 161.5 110.1
<0.001
(59.2–394) (78–394) (59.2–234.5)
CCL18 (pg/ml; median, range)
0.056 0.073 0.045
0.002
(0.01–1) (0.01–1) (0.01–0.32)
Therapies
GCs (≤10 mg/day in PDN equivalent) 51 (61.4) 35 (89.74) 15 (34.1) <0.001
Previous cyclophosphamide 39 (46.99) 25 (64.1) 14 (31.82) 0.004
Current azathioprine 15 (18.07) 8 (20.51) 7 (15.9) 0.776
Current mycophenolate mofetil 30 (36.14) 23 (58.97) 7 (15.9) <0.001
Low-dose aspirin 83 (100) 39 (100) 44 (100) —
CCBs 83 (100) 39 (100) 39 (100) —
Table 1. Characteristics of the SSc patients at baseline. Data are number and percentages (in brackets) except 
where otherwise indicated. SSc = systemic sclerosis; ILD = interstitial lung disease; SD = standard deviation; 
BMI = body mass index; lcSSc = limited cutaneous systemic sclerosis; dcSSc = diffuse cutaneous systemic 
sclerosis; RP = Raynaud phenomenon; ANA = antinuclear antibodies; ACA = anticentromere antibodies; 
ATA = anti-topoisomerase-I antibodies; Anti-RNA pol III = anti-RNA polymerase III; Ab = antibodies; 
DU = digital ulcers; mRSS = modified Rodnan Skin Score; SRC = scleroderma renal crisis; HRCT = high 
resolution computed tomography; sIL2-Rα = soluble interleukin-2 receptor alpha; GC = glucocorticoids; 
PDN = prednisone; CCBs = calcium channel blockers. *p is ILD+ versus ILD−.
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lower than the cut-off value of 0.1966, and in 10/15 (67%) of them the DLCO was lower than the 80% of predicted 
(Fig. 2C). Figure 3 shows a representative CT scan from one of these patients where no ILD could be detected at 
visual assessment, but both the CII and the DLCO were lower than the respective cut-off values (e. g. −0.3718 and 
70%). Figure 4 shows a representative case of visually detectable ILD (NSIP pattern, Goh score >20%) which was 
consistently associated with severe CII and DLCO reduction (e. g. −2.7150 and 39%, respectively).
CII correlations at follow-up. At one-year, 52 SSc patients were re-assessed for lung function. The CII 
positively correlated with the total lung capacity (TLC) (r = 0.45, p = 0.004) and the DLCO (r = 0.29, p = 0.045), 
but not with the FVC, after adjustment for baseline values. Consistently, higher values of the CII were significantly 
associated with a decrease in the odds of a DLCO < 80% of predicted (Odds Ratio- OR = 0.19, 95% Confidence 
Interval- CI:0.05–0.73; p = 0.01) but not in the odds of an FVC < 80% of predicted (OR = 0.60, 95% CI:0.25–1.44; 
p = 0.25). Moreover, the CII was associated with a clinically significant DLCO decline (e. g. a DLCO decline 
≥15%) in 7/52 (13.5%) of these patients (OR = 0.31, 95% CI:0.10–0.96; p = 0.042). Of note, although patients 
with a Goh score >20% had a three-fold risk of worsening DLCO, this association was not statistically significant 
(OR = 3.73, 95% CI:0.40 to 35.02; p = 0.249).
Discussion
To our knowledge, this is the first prospective study that evaluated a composite index (the CII) incorporating 
several CT histogram metrics (e.g. MLA, skewness, and kurtosis) in the prediction of lung function deterioration 
over the short term FU.
Our novel CII strongly discriminated between SSc patients with ILD and those without ILD, with an excellent 
reproducibility (0.99) and an excellent correlation with each of its components, thus suggesting that it provides 
complete densitometric information eliminating redundancies. Notably, the CII also strongly correlated with the 
Goh assessment9, and was significantly lower in patients with an ILD extent >20% as visually assessed. In addi-
tion, the CII was associated with the main lung function parameters suggestive of a restrictive ventilation pattern, 
as with the DLCO and subcategories of the 6-MWT at baseline. These data are in line with previous studies that 
reported similar associations of lung function parameters in SSc with each of the lung density CT histograms that 
have been hereby used to elaborate the CII16–18.
We also found that a CII cut-off of 0.1966 identified the presence of ILD with a diagnostic accuracy of 0.77 
and a sensitivity of 0.81 [95% CI:0.68–0.92] and a specificity of 0.66 [95% CI:0.52–0.80]. When we restricted the 
analysis of the CII to SSc patients with no visual evidence of ILD, we found that a significant proportion of these 
Parameter All patients (n = 83) ILD+ (n = 39) ILD− (n = 44) p*
Arterial pO2 (mmHg) at rest (21% FiO2) 83.7 ± 11.8 83 ± 2.2 84.2 ± 1.8 0.6
Arterial SpO2 (%) (median, range) 98.2 (83.5–100) 97.9 (83.5–99.5) 98.3 (95.3–100) 0.37
FVC (% predicted) 99.7 ± 25 89.2 ± 26.0 107.8 ± 21.2 0.001
TLC (% predicted) 80.9 ± 18.2 75.4 ± 20.9 85.6 ± 14.1 0.021
RV (% predicted) 78.5 ± 26.7 61.7 ± 3.6 91.7 ± 4.3 <0.001
DLCOsb (% predicted) 59 ± 19.4 51.2 ± 18.9 65.4 ± 17.5 0.001
6MWT distance (mt) (median, range) 440 (176–566) 426 (264–528) 462 (176–566) 0.24
6MWT ∆SpO2 (%) (median, range) 2 (0–18) 3 (0–18) 1 (0–14) 0.002
Table 2. Lung function assessment in the SSc patients at baseline. Data are expressed as mean ± standard 
deviation, except where otherwise indicated. SSc = systemic sclerosis; ILD = interstitial lung disease; 
pO2 = oxygen partial pressure; FiO2 = fraction of inhaled oxygen; SpO2 = oxygen saturation; FVC = forced vital 
capacity; TLC = total lung capacity; RV = residual volume; DLCOsb = single breath diffusion lung capacity for 
carbon monoxide; 6MWT = six-minute walk test; mt = meters. *p is ILD+ versus ILD−.
Parameter Unadjusted Adjusted*
pO2 (FiO2 21%) at rest, mmHg r = 0.28 (p = 0.01) r = 0.19 (p = 0.09)
% SpO2 (at blood gas analysis) r = 0.43 (p < 0.001) r = 0.46 (p < 0.001)
FVC (% predicted) r = 0.45 (p < 0.001) r = 0.48 (p < 0.001)
TLC (% predicted) r = 0.28 (p = 0.02) r = 0.28 (p = 0.02)
RV (% predicted) r = 0.52 (p < 0.001) r = 0.45 (p < 0.001)
DLCOsb (% predicted) r = 0.34 (p = 0.03) r = 0.36 (p = 0.002)
6MWT distance (mt) r = 0.33 (p < 0.001) r = 0.3 (p = 0.01)
Table 3. Correlations of the CII with lung function and exercise performance at baseline in the investigated 
SSc patients. *Adjusted for disease duration and Body Mass Index. CII = computerized integrated index; 
SSc = systemic sclerosis; pO2 = oxygen partial pressure; FiO2 = fraction of inhaled oxygen; SpO2 = oxygen 
saturation; FVC = forced vital capacity; TLC = total lung capacity; RV = residual volume; DLCOsb = single 
breath diffusion lung capacity for carbon monoxide; 6MWT = six-minute walk test; mt = meters.
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patients (34%) had a CII lower than the cut-off, and that the 67% of them had a DLCO lower than the 80% of the 
predicted value. These data suggest that this index may be more sensitive than the visual scoring and could be 
helpful for the earlier detection of ILD. In fact, the DLCO has been shown to be the best independent predictor 
of ILD progression in a recent large SSc cohort39, and in the idiopathic pulmonary fibrosis (IPF) setting40, even 
though this parameter is affected by different factors and it is not specific of fibrotic changes. However, since a 
Figure 2. (A,B) Diagnostic accuracy of the CII according to baseline values of FVC (A) and DLCO (B) by 
means of receiver-operating characteristic curve analysis. (C) Scatter plot of CII and DLCO values stratified 
according the presence of ILD. 0.1966 was the cut-off value obtained by analyzing the diagnostic accuracy of the 
CII (see Fig. 1, panel E). CII = computerized integrated index; FVC = forced vital capacity; DLCO = diffusing 
lung capacity for carbon oxide; ILD = interstitial lung disease; AUC = area under the curve; CI = confidence 
interval.
Figure 3. Comparison between quantitative and visual analysis of low-dose thin section volumetric lung 
CT in a SSc patient without visual evidence of ILD but a CII lower than the cut-off value of 0.1966 (e. g. 
CII = −0.3718). On the left, the figure shows the results from digital processing analysis: in the upper-left side 
of the image, data from the analysis of a single representative slice are given; in the lower-left side of the image 
the automatically generated averaged data from the analysis of all slices are given. Global pulmonary sampling 
has been performed and the sampled region is marked in yellow. CT = computed tomography; SSc = systemic 
sclerosis; ILD = interstitial lung disease; CII = computerized integrated index.
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major confounder of DLCO reduction in SSc is PH, our patients underwent a complete heart function evaluation 
to rule out PH cases.
We also found that the CII was significantly worse in patients with a longer disease duration, the dcSSc subset, 
and ATA positivity that has already been found to be predictive of ILD in large cohort studies41,42. Moreover, given 
the increasing amount of data providing evidence of novel circulating biomarkers of disease severity in SSc and 
of distinct SSc organ complications, we wanted to investigate the correlations of our index with serum levels of 
sIL-2Rα and CCL18. In details, we found that the CII correlates with both sIL2-Rα, that has been shown to reflect 
a more severe disease19,20, and with CCL18, that has higher serum levels in SSc patients with progressive ILD21,22.
Our study has some limitations. First, the study population size was not very large, and the prospective enroll-
ment of consecutive patients did not allow any further enrichment of patients with early dcSSc. It is possible, in 
particular, that the long disease duration recorded in our patients (that is median 12 years from RP onset) affected 
a low risk to observe a more significant lung function deterioration during FU. However, a recent analysis from 
Khanna et al.43 pointed out that lung function deterioration over-time is similar in patients with a disease dura-
tion longer or shorter than 4 years.
The major strengths of our study are the prospective design, and the use of a low-dose volumetric chest CT 
protocol, that maintains both high sensitivity and lower radiation exposure for younger subjects. Interestingly, 
after adjusting the FU analysis for baseline values, the CII was still significantly correlated with the DLCO and 
the TLC at one-year, but not with the FVC. Most importantly, the CII predicted a clinically meaningful DLCO 
reduction in a subset of patients, while the Goh score did not. It is noteworthy that other Authors recently sug-
gested that the quantitative analysis of HRCT density histograms could also be useful in assessing the risk of mor-
tality in SSc-ILD44. Collectively, these observations suggest that the CII could be relevant to address some major 
unmet needs in the management of SSc-ILD. First, it catches very early lung modifications that occur before they 
become evident at visual HRCT examination, and could therefore help in identifying patients needing an early 
treatment. Second, it is an objective and sensitive tool that could be applied to the assessment of the scleroderma 
lung before and after treatment, thus revealing minimal changes that could be missed at visual evaluation. These 
two aspects are of utmost importance in clinical practice, since basing on data available in the literature not all 
SSc patients with ILD progress, and the need for treatment is made case by case45. Moreover, despite some open 
label studies and clinical trials have shown the benefit of immunosuppressive drugs in SSc-ILD, this benefit is 
limited to slowing down or halting progression with a non trivial treatment-related toxicity thus further affect-
ing patients’ quality of life46. In this regard, Kloth et al. reported statistically significant lung texture changes at 
quantitative CT assessment in a retrospective series of 18/23 SSc patients who responded to autologous stem cell 
Figure 4. Comparison between quantitative and visual analysis of low-dose thin section volumetric lung CT in 
a SSc patient with ILD (Gho visual score >20%10; NSIP pattern) and a CII significantly lower than the cut-off 
value of 0.1966 (e. g. CII = −2.7150). On the left, the figure shows the results from digital processing analysis: 
in the upper-left side of the image, data from the analysis of a single representative slice are given; in the 
lower-left side of the image the automatically generated averaged data from the analysis of all slices are given. 
Global pulmonary sampling has been performed and the sampled region is marked in yellow. CT = computed 
tomography; SSc = systemic sclerosis; ILD = interstitial lung disease; CII = computerized integrated index; 
NSIP = non-specific interstitial pneumonia.
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transplantation in terms of FVC stabilization or improvement after 6 and 12 months47, thus suggesting that quan-
titative CT analysis might be really useful in the assessment of the response to treatment. In another retrospective 
series, Kloth et al. also explored the potential utility of CT texture analysis in differentiating active alveolitis from 
lung fibrosis in SSc patients with ILD48. However, in both studies47,48 Kloth’s et al. used a number of niche, more 
sophisticated CT texture parameters (e. g. heterogeneity, intensity, average, deviation, entropy, uniformity, and 
contrast), that require advanced and not widely available analytic tools. Therefore, as the same Authors stated, 
the daily use of such advanced CT texture analysis in SSc-ILD is still not feasible, and needs further validation in 
prospective cohort studies along with CT protocol standardization. This means that such an approach is currently 
limited to specific research settings. On the contrary, MLA, skewness, and kurtosis can be easily computed with 
open-source softwares16, can be summarized in a single index, as shown here, and could be applied in the rou-
tine clinical practice to systematically screen for early lung involvement each SSc patient and to FU the disease. 
Moreover, the correlation of textural analysis parameters with the validated outcome measures of lung function 
in SSc appears to be weaker than the correlation shown by the three basic densitometric histograms (e.g. MLA, 
skewness and kurtosis) used in our study and in previous reports49.
In conclusion, in the context of a growing interest for new methods devoted to optimize SSc-ILD detection 
and quantification15–18, our new CII could be helpful in driving the choice of patients to treat in the context of 
a more defined precision medicine approach, which ultimately will improve survival and well-being based on 
individualized and tailored patient management. To this purpose, the potential application of the CII in low-dose 
volumetric HRCT protocols for the early quantitative detection of lung density changes in SSc patients should be 
explored in larger multicenter cohort studies.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
References
 1. Tyndall, A. J. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research 
(EUSTAR) database. Ann Rheum Dis. 69, 1809–1815 (2010).
 2. Steen, V. D. & Medsger, T. A. Changes in causes of death in systemic sclerosis. Ann Rheum Dis. 66, 940–944 (2007).
 3. Trojanowska, M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol. 6, 653–660 
(2010).
 4. Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N Engl J Med. 360, 1989–2003 (2009).
 5. Greenblatt, M. B. & Aliprantis, A. O. The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep. 15, 297 
(2013).
 6. Warrick, J. H., Bhalla, M., Schabel, S. I. & Silver, R. M. High resolution computed tomography in early scleroderma lung disease. J 
Rheumatol. 18, 1520–1528 (1991).
 7. Goldin, J. G. et al. Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic 
scleroderma-related interstitial lung disease. Chest. 134, 358–367 (2008).
 8. Patiwetwitoon, S., Wangkaew, S., Euathrongchit, J., Kasitanon, N. & Louthrenoo, W. High-resolution computed tomographic 
findings in systemic sclerosis-associated interstitial lung disease: comparison between diffuse and limited systemic sclerosis. J Clin 
Rheumatol. 18, 229–233 (2012).
 9. Goh, N. S. et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 177, 1248–1254 
(2008).
 10. Moore, O. A. et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in 
systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 52, 155–160 (2013).
 11. Hoffmann-Vold, A. M. et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function 
tests in systemic sclerosis. Arthritis Rheumatol. 67, 2205–2212 (2015).
 12. Sundaram, B. et al. Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: effect of predominance and distribution 
of findings. Am J Roentgenol. 191, 1032–1039 (2008).
 13. Watadani, T. et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 266, 936–944 (2013).
 14. Hartley, P. G. et al. High resolution CT-derived measures of lung density are valid indexes of interstitial lung disease. J Appl Physiol. 
76, 271–7 (1994).
 15. Camiciottoli, G. et al. Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. 
Chest. 131, 672–681 (2007).
 16. Ariani, A. et al. Utility of an open-source DICOM viewer software (OsiriX) to assess pulmonary fibrosis in systemic sclerosis: 
preliminary results. Rheumatol Int. 34, 511–516 (2014).
 17. Ariani, A. et al. Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung 
disease related to systemic sclerosis: A multi-centric study. Mod Rheumatol. 25, 724–730 (2015).
 18. Ariani, A. et al. Quantitative CT indexes are significantly associated with exercise oxygen desaturation in interstitial lung disease 
related to systemic sclerosis. Clin Respir J. 11, 983–989 (2017).
 19. Lee, Y. J. et al. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic 
sclerosis. Clin Exp Rheumatol. 19, 69–74 (2001).
 20. Degiannis, D., Seibold, J. R., Czarnecki, M., Raskova, J. & Raska, K. Jr. Soluble interleukin-2 receptors in systemic sclerosis patients. 
Arthritis Rheum. 33, 375–380 (1990).
 21. Schupp, J. et al. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J. 43, 
1530–1532 (2014).
 22. Hoffmann-Vold, A. M. et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis 
progression, and reduced survival in systemic sclerosis. Chest. 150, 299–306 (2016).
 23. van den Hoogen, F. et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League 
Against Rheumatism Collaborative Initiative. Arthritis Rheumatol. 65, 2737–2747 (2013).
 24. LeRoy, E. C. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 15, 202–205 (1988).
 25. Valentini, G., Medsger, T. A. Jr., Silman, A. J. & Bombardieri, S. Conclusion and identification of the core set of variables to be used 
in clinical investigations. Clin Exp Rheumatol. 21(3 Suppl 29), S47–48 (2003).
 26. Vettori, S. et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked 
by elevated interleukin-33 levels. J Clin Immunol. 34, 663–668 (2014).
 27. Miller, M. R. et al. ATS/ERS Task Force. Standardization of spirometry. Eur Respir J. 26, 319–338 (2005).
 28. Wanger, J. et al. Standardization of the measurement of lung volumes. Eur Respir J. 26, 511–522 (2005).
9SCIENTIFIC REPORTS |          (2019) 9:9468  | https://doi.org/10.1038/s41598-019-45990-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
 29. Macintyre, N. et al. Standardization of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 26, 
720–735 (2005).
 30. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-
minute walk test. Am J Respir Crit Care Med. 166, 111–117 (2002).
 31. D’Alto, M. et al. Tissue Doppler imaging in systemic sclerosis: a 3-year longitudinal study. Semin Arthritis Rheum. 43, 673–680 
(2014).
 32. Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the 
American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 28, 1–39 
(2015).
 33. Zwirewich, C. V., Mayo, J. R. & Muller, N. L. Low-dose high-resolution CT of the lung parenchyma. Radiology. 180, 413–417 (1991).
 34. Lee, K. S. et al. Chronic infiltrative lung disease: comparison of diagnostic accuracies of radiography and low- and conventional-dose 
thin section CT. Radiology. 191, 669–673 (1994).
 35. Mayo, J. R. et al. Reduced radiation dose helical chest CT: effect on reader evaluation of structures and lung findings. Radiology. 232, 
749–756 (2004).
 36. Best, A. C. et al. Quantitative CT indexes in idiopathic pulmonary fibrosis: relationship with physiologic impairment. Radiology. 
228, 407–414 (2003).
 37. Yao, F., Müller, H. G. & Wang, J. L. Functional data analysis for sparse longitudinal data. J Am Stat Assoc. 100, 577–590 (2005).
 38. Lawrence, I. & Kuei, L. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 45, 255–268 (1989).
 39. Tashkin, D. P. et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and 
clinical features of systemic sclerosis. Ann Rheum Dis. 75, 374–381 (2016).
 40. Raghu, G. et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An 
Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 192, e3–e19 (2015).
 41. Assassi, S. et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS 
cohort. Arthritis Res Ther. 12, R166 (2010).
 42. Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 66, 
1625–1635 (2014).
 43. Khanna, D. et al. Clinical course of lung physiology in patients with Scleroderma and Interstitial Lung Disease. Analysis of the 
Scleroderma Lung Study placebo group. Arthritis Rheum. 63, 3078–3085 (2011).
 44. Ariani, A. et al. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung 
disease related to systemic sclerosis. Rheumatology. 56, 922–927 (2017).
 45. Cottin, V. & Brown, K. K. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 20, 13 (2019).
 46. Roofeh, D., Jaafar, S., Vummidi, D. & Khanna, D. Management of systemic sclerosis-associated interstitial lung disease. Curr Opin 
Rheumatol. 31, 241–249 (2019).
 47. Kloth, C. et al. Chest CT texture analysis for response assessment in systemic sclerosis. Eur J Radiol. 101, 50–58 (2018).
 48. Kloth, C. et al. Differences in texture analysis parameters between active alveolitis and lung fibrosis in chest CT of patients with 
systemic sclerosis: a feasibility study. Acad Radiol. 24, 1596–1603 (2017).
 49. van Royen, F. S. et al. Automated CT quantification methods for the assessment of interstitial lung disease in collagen vascular 
diseases: A systematic review. Eur J Radiol. 112, 200–206 (2019).
Acknowledgements
S.V. received consultancy fees from Boehringer-Ingelheim and Thermo-Fischer, speeking fees and/or educational 
support from Abbvie, Roche, Pfizer, BMS. However, no specific funding was received to carry out the work 
described in this manuscript.
Author Contributions
M.B., G.R. and S.V. designed the study, acquired data, drafted and critically revised the manuscript. D.B. was 
responsible for the statistical analysis plan and oversight of the data analysis, drafted and critically revised the 
manuscript. M.D., P.A., A.B., A.C., E.R., B.R. and T.V. acquired data and critically revised the manuscript. A.S. 
and N.S. contributed to study conception and critically revised the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-45990-7.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
